Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281567235> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W4281567235 abstract "Abstract There are various effective combinations of therapy in the neoadjuvant treatment of human epidermal growth factor receptor 2 (Her-2) positive breast cancer (BC). One of the best-known of these treatments is the dual blockade with pertuzumab and trastuzumab, which is an anti-Her-2 treatment added to chemotherapy. The aim of this study was to retrospectively investigate the rate of pathological complete response (pCR) and markers predicting this response for trastuzumab and pertuzumab-containing regimens compared to trastuzumab-containing regimens for stage II to III HER-2 positive BC. In this study, we retrospectively analyzed the data of patients with Her-2 positive advanced BC who were treated with trastuzumab or trastuzumab and pertuzumab in addition to neoadjuvant chemotherapy. Patients were classified according to their pre-treatment clinical stages, hormone receptor status, Her-2 immuno-histochemical score, ki-67 index, neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and prognostic nutritional index (PNI) ratio. The cut-off values of these parameters were calculated by performing a Roc-Curve analysis. Patients with and without pCR with neoadjuvant therapy were evaluated. For NLR, it was 1.9 ± 0.85 in patients with pCR and 2.4 ± 0.83 in patients without pCR. For PLR it was 112 ± 53.3 and 129.4 ± 36.2, respectively. For PNI, it was 51.6 ± 5.8 and 48.1 ± 5.9. Low NLR and PLR as well as high PNI were significantly associated with pCR. In addition, the pCR of patients with Hormone Receptor negativity and dual Her-2 blockade was statistically significant. This is the first study in the literature to show that prognostic scores such as NLR, PLR, and PNI have statistically significant benefits on pCR in patients treated with the neoadjuvant dual bloc" @default.
- W4281567235 created "2022-05-27" @default.
- W4281567235 creator A5050232988 @default.
- W4281567235 creator A5075580269 @default.
- W4281567235 date "2022-05-26" @default.
- W4281567235 modified "2023-09-23" @default.
- W4281567235 title "Effect of Inflammatory Markers on the Pathologic Complete Response in the Neoadjuvan Treatment of Her-2 Positive Local Advanced Breast Cancer" @default.
- W4281567235 doi "https://doi.org/10.21203/rs.3.rs-1666104/v1" @default.
- W4281567235 hasPublicationYear "2022" @default.
- W4281567235 type Work @default.
- W4281567235 citedByCount "0" @default.
- W4281567235 crossrefType "posted-content" @default.
- W4281567235 hasAuthorship W4281567235A5050232988 @default.
- W4281567235 hasAuthorship W4281567235A5075580269 @default.
- W4281567235 hasBestOaLocation W42815672351 @default.
- W4281567235 hasConcept C121608353 @default.
- W4281567235 hasConcept C126322002 @default.
- W4281567235 hasConcept C143998085 @default.
- W4281567235 hasConcept C146357865 @default.
- W4281567235 hasConcept C151730666 @default.
- W4281567235 hasConcept C207886595 @default.
- W4281567235 hasConcept C23589133 @default.
- W4281567235 hasConcept C2776694085 @default.
- W4281567235 hasConcept C2778292576 @default.
- W4281567235 hasConcept C2779786085 @default.
- W4281567235 hasConcept C2781164504 @default.
- W4281567235 hasConcept C530470458 @default.
- W4281567235 hasConcept C71924100 @default.
- W4281567235 hasConcept C86803240 @default.
- W4281567235 hasConcept C90924648 @default.
- W4281567235 hasConceptScore W4281567235C121608353 @default.
- W4281567235 hasConceptScore W4281567235C126322002 @default.
- W4281567235 hasConceptScore W4281567235C143998085 @default.
- W4281567235 hasConceptScore W4281567235C146357865 @default.
- W4281567235 hasConceptScore W4281567235C151730666 @default.
- W4281567235 hasConceptScore W4281567235C207886595 @default.
- W4281567235 hasConceptScore W4281567235C23589133 @default.
- W4281567235 hasConceptScore W4281567235C2776694085 @default.
- W4281567235 hasConceptScore W4281567235C2778292576 @default.
- W4281567235 hasConceptScore W4281567235C2779786085 @default.
- W4281567235 hasConceptScore W4281567235C2781164504 @default.
- W4281567235 hasConceptScore W4281567235C530470458 @default.
- W4281567235 hasConceptScore W4281567235C71924100 @default.
- W4281567235 hasConceptScore W4281567235C86803240 @default.
- W4281567235 hasConceptScore W4281567235C90924648 @default.
- W4281567235 hasLocation W42815672351 @default.
- W4281567235 hasOpenAccess W4281567235 @default.
- W4281567235 hasPrimaryLocation W42815672351 @default.
- W4281567235 hasRelatedWork W2075990854 @default.
- W4281567235 hasRelatedWork W2270317063 @default.
- W4281567235 hasRelatedWork W2381572134 @default.
- W4281567235 hasRelatedWork W2593886517 @default.
- W4281567235 hasRelatedWork W2751857407 @default.
- W4281567235 hasRelatedWork W2760874931 @default.
- W4281567235 hasRelatedWork W3092162558 @default.
- W4281567235 hasRelatedWork W4205955288 @default.
- W4281567235 hasRelatedWork W4286632023 @default.
- W4281567235 hasRelatedWork W4322772378 @default.
- W4281567235 isParatext "false" @default.
- W4281567235 isRetracted "false" @default.
- W4281567235 workType "article" @default.